Allegations of undisclosed safety data have emerged amid a growing wave of litigation in the United States linking the herbicide paraquat to Parkinson’s disease, according to court filings and media reports. Plaintiffs say documents show manufacturers withheld information from regulators; Syngenta, identified in reports as the long‑time maker of paraquat, has denied failing to provide relevant data to the U.S. Environmental Protection Agency.
Allegations and company response
Lawsuits in the U.S. contend that safety evidence about paraquat’s human health risks was not adequately disclosed to U.S. authorities. Syngenta has pushed back against claims that it kept data from the EPA, maintaining that it complied with regulatory obligations. The company and its legal teams are confronting multiple suits that seek damages for alleged links between paraquat exposure and Parkinson’s disease.
Global regulatory context
Concerns about paraquat are not new: Sweden called for a ban as early as 2004, and dozens of other countries have since prohibited the chemical as scientific evidence about its risks accumulated. The Chinese government, which is reported to own Syngenta, halted domestic use about a decade ago after conducting its own safety studies that officials said raised troubling findings.
Recent U.S. and state actions
In the United States, paraquat remains on the market despite those international restrictions, though state regulators have begun to act. Vermont and California have recently moved to ban the herbicide; California regulators said in August that paraquat manufacturers had agreed voluntarily to cease sales in the state after new research there identified health concerns associated with its use.
Federal scrutiny and political pressure
The legal developments have coincided with growing calls from some lawmakers for a nationwide prohibition. Several federal legislators have urged the EPA to consider stricter controls or an outright ban, citing the body of scientific research that has found an association between paraquat exposure and Parkinson’s disease. The dispute over what data were shared with regulators is likely to be a focal point of both the litigation and any further policy debate.
As courts and regulators continue to examine the herbicide’s safety record, industry statements, scientific studies and newly disclosed documents are expected to shape the next phase of legal and regulatory responses in the U.S. and abroad.